nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.559	1	CiPCiCtD
Temsirolimus—kidney cancer—thyroid cancer	0.296	1	CtDrD
Temsirolimus—CYP3A7—Sorafenib—thyroid cancer	0.0134	0.191	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0134	0.191	CbGbCtD
Temsirolimus—CYP3A5—Sorafenib—thyroid cancer	0.0101	0.143	CbGbCtD
Temsirolimus—ABCB1—Sorafenib—thyroid cancer	0.00656	0.0934	CbGbCtD
Temsirolimus—CYP3A4—Vandetanib—thyroid cancer	0.00652	0.0928	CbGbCtD
Temsirolimus—CYP2D6—Sorafenib—thyroid cancer	0.00618	0.088	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—thyroid cancer	0.00398	0.0567	CbGbCtD
Temsirolimus—CYP3A4—Sorafenib—thyroid cancer	0.00393	0.0559	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—thyroid cancer	0.00375	0.0534	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—thyroid cancer	0.00238	0.0339	CbGbCtD
Temsirolimus—Pruritus—Vandetanib—thyroid cancer	7.65e-05	0.00135	CcSEcCtD
Temsirolimus—Hypocalcaemia—Doxorubicin—thyroid cancer	7.64e-05	0.00134	CcSEcCtD
Temsirolimus—Arthralgia—Sorafenib—thyroid cancer	7.61e-05	0.00134	CcSEcCtD
Temsirolimus—Myalgia—Sorafenib—thyroid cancer	7.61e-05	0.00134	CcSEcCtD
Temsirolimus—Herpes simplex—Doxorubicin—thyroid cancer	7.59e-05	0.00134	CcSEcCtD
Temsirolimus—Glossitis—Doxorubicin—thyroid cancer	7.59e-05	0.00134	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	7.56e-05	0.00133	CcSEcCtD
Temsirolimus—Phosphatase alkaline increased—Epirubicin—thyroid cancer	7.56e-05	0.00133	CcSEcCtD
Temsirolimus—Pulmonary embolism—Epirubicin—thyroid cancer	7.56e-05	0.00133	CcSEcCtD
Temsirolimus—Diarrhoea—Vandetanib—thyroid cancer	7.4e-05	0.0013	CcSEcCtD
Temsirolimus—Blood bilirubin increased—Doxorubicin—thyroid cancer	7.39e-05	0.0013	CcSEcCtD
Temsirolimus—Cystitis noninfective—Epirubicin—thyroid cancer	7.38e-05	0.0013	CcSEcCtD
Temsirolimus—Creatinine increased—Doxorubicin—thyroid cancer	7.35e-05	0.00129	CcSEcCtD
Temsirolimus—Cystitis—Epirubicin—thyroid cancer	7.3e-05	0.00128	CcSEcCtD
Temsirolimus—Anaphylactic shock—Sorafenib—thyroid cancer	7.3e-05	0.00128	CcSEcCtD
Temsirolimus—Infection—Sorafenib—thyroid cancer	7.25e-05	0.00128	CcSEcCtD
Temsirolimus—Candida infection—Epirubicin—thyroid cancer	7.22e-05	0.00127	CcSEcCtD
Temsirolimus—Fluid retention—Epirubicin—thyroid cancer	7.18e-05	0.00126	CcSEcCtD
Temsirolimus—Nervous system disorder—Sorafenib—thyroid cancer	7.16e-05	0.00126	CcSEcCtD
Temsirolimus—Dizziness—Vandetanib—thyroid cancer	7.15e-05	0.00126	CcSEcCtD
Temsirolimus—Thrombocytopenia—Sorafenib—thyroid cancer	7.15e-05	0.00126	CcSEcCtD
Temsirolimus—Skin disorder—Sorafenib—thyroid cancer	7.09e-05	0.00125	CcSEcCtD
Temsirolimus—Pulmonary embolism—Doxorubicin—thyroid cancer	6.99e-05	0.00123	CcSEcCtD
Temsirolimus—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	6.99e-05	0.00123	CcSEcCtD
Temsirolimus—Anorexia—Sorafenib—thyroid cancer	6.96e-05	0.00122	CcSEcCtD
Temsirolimus—Vomiting—Vandetanib—thyroid cancer	6.88e-05	0.00121	CcSEcCtD
Temsirolimus—Rash maculo-papular—Epirubicin—thyroid cancer	6.87e-05	0.00121	CcSEcCtD
Temsirolimus—Bladder pain—Epirubicin—thyroid cancer	6.83e-05	0.0012	CcSEcCtD
Temsirolimus—Ecchymosis—Epirubicin—thyroid cancer	6.83e-05	0.0012	CcSEcCtD
Temsirolimus—Mouth ulceration—Epirubicin—thyroid cancer	6.83e-05	0.0012	CcSEcCtD
Temsirolimus—Cystitis noninfective—Doxorubicin—thyroid cancer	6.83e-05	0.0012	CcSEcCtD
Temsirolimus—Rash—Vandetanib—thyroid cancer	6.82e-05	0.0012	CcSEcCtD
Temsirolimus—Dermatitis—Vandetanib—thyroid cancer	6.81e-05	0.0012	CcSEcCtD
Temsirolimus—Headache—Vandetanib—thyroid cancer	6.78e-05	0.00119	CcSEcCtD
Temsirolimus—Cystitis—Doxorubicin—thyroid cancer	6.75e-05	0.00119	CcSEcCtD
Temsirolimus—Candida infection—Doxorubicin—thyroid cancer	6.68e-05	0.00118	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Sorafenib—thyroid cancer	6.65e-05	0.00117	CcSEcCtD
Temsirolimus—Fluid retention—Doxorubicin—thyroid cancer	6.64e-05	0.00117	CcSEcCtD
Temsirolimus—Sepsis—Epirubicin—thyroid cancer	6.56e-05	0.00115	CcSEcCtD
Temsirolimus—Dyspnoea—Sorafenib—thyroid cancer	6.51e-05	0.00115	CcSEcCtD
Temsirolimus—Nausea—Vandetanib—thyroid cancer	6.43e-05	0.00113	CcSEcCtD
Temsirolimus—Rash maculo-papular—Doxorubicin—thyroid cancer	6.36e-05	0.00112	CcSEcCtD
Temsirolimus—Decreased appetite—Sorafenib—thyroid cancer	6.34e-05	0.00112	CcSEcCtD
Temsirolimus—Thrombophlebitis—Epirubicin—thyroid cancer	6.34e-05	0.00112	CcSEcCtD
Temsirolimus—Ecchymosis—Doxorubicin—thyroid cancer	6.32e-05	0.00111	CcSEcCtD
Temsirolimus—Bladder pain—Doxorubicin—thyroid cancer	6.32e-05	0.00111	CcSEcCtD
Temsirolimus—Mouth ulceration—Doxorubicin—thyroid cancer	6.32e-05	0.00111	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	6.31e-05	0.00111	CcSEcCtD
Temsirolimus—Diabetes mellitus—Epirubicin—thyroid cancer	6.31e-05	0.00111	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Sorafenib—thyroid cancer	6.3e-05	0.00111	CcSEcCtD
Temsirolimus—Fatigue—Sorafenib—thyroid cancer	6.29e-05	0.00111	CcSEcCtD
Temsirolimus—Pain—Sorafenib—thyroid cancer	6.24e-05	0.0011	CcSEcCtD
Temsirolimus—Constipation—Sorafenib—thyroid cancer	6.24e-05	0.0011	CcSEcCtD
Temsirolimus—Eczema—Epirubicin—thyroid cancer	6.11e-05	0.00107	CcSEcCtD
Temsirolimus—Sepsis—Doxorubicin—thyroid cancer	6.07e-05	0.00107	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Sorafenib—thyroid cancer	5.97e-05	0.00105	CcSEcCtD
Temsirolimus—Thrombophlebitis—Doxorubicin—thyroid cancer	5.87e-05	0.00103	CcSEcCtD
Temsirolimus—Diabetes mellitus—Doxorubicin—thyroid cancer	5.84e-05	0.00103	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	5.84e-05	0.00103	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Epirubicin—thyroid cancer	5.82e-05	0.00102	CcSEcCtD
Temsirolimus—Abdominal pain—Sorafenib—thyroid cancer	5.77e-05	0.00102	CcSEcCtD
Temsirolimus—Body temperature increased—Sorafenib—thyroid cancer	5.77e-05	0.00102	CcSEcCtD
Temsirolimus—Dermatitis bullous—Epirubicin—thyroid cancer	5.74e-05	0.00101	CcSEcCtD
Temsirolimus—Eczema—Doxorubicin—thyroid cancer	5.65e-05	0.000995	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	5.49e-05	0.000966	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Doxorubicin—thyroid cancer	5.38e-05	0.000947	CcSEcCtD
Temsirolimus—Hypersensitivity—Sorafenib—thyroid cancer	5.38e-05	0.000946	CcSEcCtD
Temsirolimus—Dermatitis bullous—Doxorubicin—thyroid cancer	5.31e-05	0.000935	CcSEcCtD
Temsirolimus—Face oedema—Epirubicin—thyroid cancer	5.3e-05	0.000933	CcSEcCtD
Temsirolimus—Asthenia—Sorafenib—thyroid cancer	5.24e-05	0.000922	CcSEcCtD
Temsirolimus—Pruritus—Sorafenib—thyroid cancer	5.16e-05	0.000909	CcSEcCtD
Temsirolimus—Blood creatinine increased—Epirubicin—thyroid cancer	5.14e-05	0.000905	CcSEcCtD
Temsirolimus—Dehydration—Epirubicin—thyroid cancer	5.1e-05	0.000898	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	5.08e-05	0.000894	CcSEcCtD
Temsirolimus—Dry skin—Epirubicin—thyroid cancer	5.03e-05	0.000885	CcSEcCtD
Temsirolimus—Hypokalaemia—Epirubicin—thyroid cancer	4.99e-05	0.000879	CcSEcCtD
Temsirolimus—Diarrhoea—Sorafenib—thyroid cancer	4.99e-05	0.000879	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	4.94e-05	0.00087	CcSEcCtD
Temsirolimus—Face oedema—Doxorubicin—thyroid cancer	4.9e-05	0.000863	CcSEcCtD
Temsirolimus—Gastritis—Epirubicin—thyroid cancer	4.86e-05	0.000855	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Epirubicin—thyroid cancer	4.84e-05	0.000852	CcSEcCtD
Temsirolimus—Dizziness—Sorafenib—thyroid cancer	4.83e-05	0.00085	CcSEcCtD
Temsirolimus—Abdominal distension—Epirubicin—thyroid cancer	4.77e-05	0.00084	CcSEcCtD
Temsirolimus—Blood creatinine increased—Doxorubicin—thyroid cancer	4.76e-05	0.000837	CcSEcCtD
Temsirolimus—Influenza—Epirubicin—thyroid cancer	4.74e-05	0.000835	CcSEcCtD
Temsirolimus—Dysphagia—Epirubicin—thyroid cancer	4.74e-05	0.000835	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—thyroid cancer	4.72e-05	0.000831	CcSEcCtD
Temsirolimus—Dry skin—Doxorubicin—thyroid cancer	4.65e-05	0.000819	CcSEcCtD
Temsirolimus—Vomiting—Sorafenib—thyroid cancer	4.64e-05	0.000817	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—thyroid cancer	4.62e-05	0.000813	CcSEcCtD
Temsirolimus—Rash—Sorafenib—thyroid cancer	4.6e-05	0.00081	CcSEcCtD
Temsirolimus—Dermatitis—Sorafenib—thyroid cancer	4.6e-05	0.000809	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	4.57e-05	0.000805	CcSEcCtD
Temsirolimus—Headache—Sorafenib—thyroid cancer	4.57e-05	0.000805	CcSEcCtD
Temsirolimus—Bronchitis—Epirubicin—thyroid cancer	4.56e-05	0.000803	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—thyroid cancer	4.49e-05	0.000791	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	4.48e-05	0.000788	CcSEcCtD
Temsirolimus—Dysuria—Epirubicin—thyroid cancer	4.43e-05	0.000781	CcSEcCtD
Temsirolimus—Neutropenia—Epirubicin—thyroid cancer	4.43e-05	0.000781	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—thyroid cancer	4.42e-05	0.000778	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Epirubicin—thyroid cancer	4.41e-05	0.000776	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—thyroid cancer	4.39e-05	0.000772	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—thyroid cancer	4.39e-05	0.000772	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—thyroid cancer	4.38e-05	0.000771	CcSEcCtD
Temsirolimus—Nausea—Sorafenib—thyroid cancer	4.33e-05	0.000763	CcSEcCtD
Temsirolimus—Weight decreased—Epirubicin—thyroid cancer	4.29e-05	0.000755	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—thyroid cancer	4.28e-05	0.000753	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—thyroid cancer	4.25e-05	0.000749	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—thyroid cancer	4.23e-05	0.000744	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—thyroid cancer	4.23e-05	0.000744	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—thyroid cancer	4.22e-05	0.000743	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	4.19e-05	0.000738	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—thyroid cancer	4.16e-05	0.000732	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—thyroid cancer	4.12e-05	0.000726	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—thyroid cancer	4.11e-05	0.000724	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—thyroid cancer	4.11e-05	0.000724	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—thyroid cancer	4.1e-05	0.000722	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—thyroid cancer	4.1e-05	0.000722	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—thyroid cancer	4.08e-05	0.000718	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—thyroid cancer	4.05e-05	0.000714	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—thyroid cancer	4.03e-05	0.00071	CcSEcCtD
Temsirolimus—Epistaxis—Epirubicin—thyroid cancer	3.99e-05	0.000702	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—thyroid cancer	3.97e-05	0.000699	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—thyroid cancer	3.97e-05	0.000698	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—thyroid cancer	3.96e-05	0.000697	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—thyroid cancer	3.94e-05	0.000693	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—thyroid cancer	3.91e-05	0.000689	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—thyroid cancer	3.91e-05	0.000689	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	3.88e-05	0.000683	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—thyroid cancer	3.85e-05	0.000677	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—thyroid cancer	3.81e-05	0.000671	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—thyroid cancer	3.81e-05	0.00067	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—thyroid cancer	3.8e-05	0.00067	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—thyroid cancer	3.8e-05	0.00067	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—thyroid cancer	3.77e-05	0.000663	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—thyroid cancer	3.75e-05	0.00066	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—thyroid cancer	3.74e-05	0.000658	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—thyroid cancer	3.73e-05	0.000657	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—thyroid cancer	3.73e-05	0.000657	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—thyroid cancer	3.72e-05	0.000655	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—thyroid cancer	3.69e-05	0.00065	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—thyroid cancer	3.67e-05	0.000646	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—thyroid cancer	3.59e-05	0.000632	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—thyroid cancer	3.55e-05	0.000625	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—thyroid cancer	3.52e-05	0.00062	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—thyroid cancer	3.52e-05	0.00062	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—thyroid cancer	3.49e-05	0.000614	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—thyroid cancer	3.47e-05	0.000611	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—thyroid cancer	3.46e-05	0.000609	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—thyroid cancer	3.45e-05	0.000608	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—thyroid cancer	3.44e-05	0.000606	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—thyroid cancer	3.44e-05	0.000606	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—thyroid cancer	3.43e-05	0.000604	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—thyroid cancer	3.42e-05	0.000602	CcSEcCtD
Temsirolimus—Chills—Epirubicin—thyroid cancer	3.41e-05	0.0006	CcSEcCtD
Temsirolimus—Mental disorder—Epirubicin—thyroid cancer	3.33e-05	0.000585	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—thyroid cancer	3.32e-05	0.000585	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—thyroid cancer	3.3e-05	0.000582	CcSEcCtD
Temsirolimus—Malnutrition—Epirubicin—thyroid cancer	3.3e-05	0.000582	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—thyroid cancer	3.28e-05	0.000578	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—thyroid cancer	3.26e-05	0.000574	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—thyroid cancer	3.24e-05	0.00057	CcSEcCtD
Temsirolimus—Back pain—Epirubicin—thyroid cancer	3.2e-05	0.000563	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—thyroid cancer	3.19e-05	0.000561	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—thyroid cancer	3.17e-05	0.000558	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—thyroid cancer	3.17e-05	0.000557	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—thyroid cancer	3.15e-05	0.000555	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—thyroid cancer	3.08e-05	0.000542	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—thyroid cancer	3.06e-05	0.000538	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—thyroid cancer	3.06e-05	0.000538	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—thyroid cancer	3.05e-05	0.000538	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—thyroid cancer	2.99e-05	0.000527	CcSEcCtD
Temsirolimus—Leukopenia—Epirubicin—thyroid cancer	2.96e-05	0.000521	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—thyroid cancer	2.96e-05	0.000521	CcSEcCtD
Temsirolimus—Cough—Epirubicin—thyroid cancer	2.88e-05	0.000508	CcSEcCtD
Temsirolimus—Convulsion—Epirubicin—thyroid cancer	2.86e-05	0.000504	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—thyroid cancer	2.85e-05	0.000502	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—thyroid cancer	2.83e-05	0.000497	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—thyroid cancer	2.81e-05	0.000495	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—thyroid cancer	2.81e-05	0.000495	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—thyroid cancer	2.81e-05	0.000495	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—thyroid cancer	2.8e-05	0.000494	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	2.79e-05	0.000492	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—thyroid cancer	2.74e-05	0.000482	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—thyroid cancer	2.7e-05	0.000475	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—thyroid cancer	2.7e-05	0.000475	CcSEcCtD
Temsirolimus—Infection—Epirubicin—thyroid cancer	2.68e-05	0.000472	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—thyroid cancer	2.67e-05	0.00047	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—thyroid cancer	2.65e-05	0.000466	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—thyroid cancer	2.64e-05	0.000466	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—thyroid cancer	2.64e-05	0.000465	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—thyroid cancer	2.64e-05	0.000465	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—thyroid cancer	2.62e-05	0.000461	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—thyroid cancer	2.6e-05	0.000458	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—thyroid cancer	2.6e-05	0.000458	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—thyroid cancer	2.6e-05	0.000458	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—thyroid cancer	2.59e-05	0.000457	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	2.59e-05	0.000455	CcSEcCtD
Temsirolimus—Anorexia—Epirubicin—thyroid cancer	2.57e-05	0.000453	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—thyroid cancer	2.5e-05	0.000439	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—thyroid cancer	2.5e-05	0.000439	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—thyroid cancer	2.48e-05	0.000436	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—thyroid cancer	2.46e-05	0.000433	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—thyroid cancer	2.45e-05	0.000431	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—thyroid cancer	2.44e-05	0.00043	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—thyroid cancer	2.44e-05	0.000429	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—thyroid cancer	2.42e-05	0.000427	CcSEcCtD
Temsirolimus—Dyspnoea—Epirubicin—thyroid cancer	2.4e-05	0.000423	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—thyroid cancer	2.4e-05	0.000422	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—thyroid cancer	2.38e-05	0.000419	CcSEcCtD
Temsirolimus—Decreased appetite—Epirubicin—thyroid cancer	2.34e-05	0.000413	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—thyroid cancer	2.33e-05	0.00041	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—thyroid cancer	2.33e-05	0.000409	CcSEcCtD
Temsirolimus—Pain—Epirubicin—thyroid cancer	2.31e-05	0.000406	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—thyroid cancer	2.31e-05	0.000406	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	2.27e-05	0.0004	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—thyroid cancer	2.26e-05	0.000397	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—thyroid cancer	2.22e-05	0.000392	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—thyroid cancer	2.22e-05	0.000391	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Epirubicin—thyroid cancer	2.21e-05	0.000388	CcSEcCtD
Temsirolimus—Decreased appetite—Doxorubicin—thyroid cancer	2.17e-05	0.000382	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—thyroid cancer	2.15e-05	0.000379	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—thyroid cancer	2.15e-05	0.000379	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—thyroid cancer	2.13e-05	0.000376	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—thyroid cancer	2.13e-05	0.000376	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—thyroid cancer	2.13e-05	0.000375	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—thyroid cancer	2.13e-05	0.000375	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Doxorubicin—thyroid cancer	2.04e-05	0.000359	CcSEcCtD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—thyroid cancer	2e-05	0.00108	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Epirubicin—thyroid cancer	1.99e-05	0.00035	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—BRAF—thyroid cancer	1.98e-05	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CDK1—thyroid cancer	1.98e-05	0.00107	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.97e-05	0.00107	CbGpPWpGaD
Temsirolimus—Abdominal pain—Doxorubicin—thyroid cancer	1.97e-05	0.000347	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—thyroid cancer	1.97e-05	0.000347	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—NRAS—thyroid cancer	1.97e-05	0.00107	CbGpPWpGaD
Temsirolimus—CYP2D6—Biological oxidations—RXRA—thyroid cancer	1.96e-05	0.00106	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—NRAS—thyroid cancer	1.96e-05	0.00106	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TSHR—thyroid cancer	1.95e-05	0.00106	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—NRAS—thyroid cancer	1.95e-05	0.00106	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—NRAS—thyroid cancer	1.94e-05	0.00105	CbGpPWpGaD
Temsirolimus—Asthenia—Epirubicin—thyroid cancer	1.94e-05	0.000341	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—PRKAR1A—thyroid cancer	1.92e-05	0.00104	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	1.91e-05	0.00104	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—thyroid cancer	1.91e-05	0.00104	CbGpPWpGaD
Temsirolimus—Pruritus—Epirubicin—thyroid cancer	1.91e-05	0.000336	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—IFNA2—thyroid cancer	1.9e-05	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—PTEN—thyroid cancer	1.89e-05	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—AKT1—thyroid cancer	1.89e-05	0.00103	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CDK1—thyroid cancer	1.89e-05	0.00103	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—HRAS—thyroid cancer	1.89e-05	0.00102	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—KRAS—thyroid cancer	1.89e-05	0.00102	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—HRAS—thyroid cancer	1.87e-05	0.00102	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—AKT1—thyroid cancer	1.85e-05	0.001	CbGpPWpGaD
Temsirolimus—Diarrhoea—Epirubicin—thyroid cancer	1.85e-05	0.000325	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—thyroid cancer	1.84e-05	0.000324	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—MEN1—thyroid cancer	1.84e-05	0.000997	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—AKT1—thyroid cancer	1.83e-05	0.000995	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—NRAS—thyroid cancer	1.83e-05	0.000991	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—thyroid cancer	1.83e-05	0.000991	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—NRAS—thyroid cancer	1.83e-05	0.000991	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—thyroid cancer	1.81e-05	0.000983	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—NRAS—thyroid cancer	1.81e-05	0.000982	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HPGD—thyroid cancer	1.81e-05	0.00098	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—KRAS—thyroid cancer	1.8e-05	0.000979	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—NRAS—thyroid cancer	1.79e-05	0.000973	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—AKT1—thyroid cancer	1.79e-05	0.000972	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thyroid cancer	1.79e-05	0.000972	CbGpPWpGaD
Temsirolimus—Asthenia—Doxorubicin—thyroid cancer	1.79e-05	0.000315	CcSEcCtD
Temsirolimus—MTOR—Signaling by PDGF—NRAS—thyroid cancer	1.79e-05	0.000969	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	1.78e-05	0.000968	CbGpPWpGaD
Temsirolimus—Dizziness—Epirubicin—thyroid cancer	1.78e-05	0.000314	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—KRAS—thyroid cancer	1.78e-05	0.000963	CbGpPWpGaD
Temsirolimus—Pruritus—Doxorubicin—thyroid cancer	1.77e-05	0.000311	CcSEcCtD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—thyroid cancer	1.76e-05	0.000957	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NDUFA13—thyroid cancer	1.72e-05	0.000935	CbGpPWpGaD
Temsirolimus—Vomiting—Epirubicin—thyroid cancer	1.71e-05	0.000302	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—thyroid cancer	1.71e-05	0.000301	CcSEcCtD
Temsirolimus—Rash—Epirubicin—thyroid cancer	1.7e-05	0.000299	CcSEcCtD
Temsirolimus—MTOR—Immune System—TPR—thyroid cancer	1.7e-05	0.000922	CbGpPWpGaD
Temsirolimus—Dermatitis—Epirubicin—thyroid cancer	1.7e-05	0.000299	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—KRAS—thyroid cancer	1.7e-05	0.00092	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—NRAS—thyroid cancer	1.69e-05	0.000917	CbGpPWpGaD
Temsirolimus—Headache—Epirubicin—thyroid cancer	1.69e-05	0.000297	CcSEcCtD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—thyroid cancer	1.69e-05	0.000915	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—KRAS—thyroid cancer	1.69e-05	0.000915	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—LGALS3—thyroid cancer	1.69e-05	0.000915	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—KRAS—thyroid cancer	1.68e-05	0.000911	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PRKAR1A—thyroid cancer	1.67e-05	0.000907	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—KRAS—thyroid cancer	1.67e-05	0.000906	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—AKT1—thyroid cancer	1.67e-05	0.000904	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTCH1—thyroid cancer	1.66e-05	0.000902	CbGpPWpGaD
Temsirolimus—Dizziness—Doxorubicin—thyroid cancer	1.65e-05	0.00029	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—thyroid cancer	1.65e-05	0.000893	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CHST14—thyroid cancer	1.62e-05	0.000879	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	1.62e-05	0.000877	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—HRAS—thyroid cancer	1.6e-05	0.000869	CbGpPWpGaD
Temsirolimus—Nausea—Epirubicin—thyroid cancer	1.6e-05	0.000282	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—NRG1—thyroid cancer	1.59e-05	0.000861	CbGpPWpGaD
Temsirolimus—Vomiting—Doxorubicin—thyroid cancer	1.59e-05	0.000279	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	1.59e-05	0.000861	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—HRAS—thyroid cancer	1.58e-05	0.000855	CbGpPWpGaD
Temsirolimus—Rash—Doxorubicin—thyroid cancer	1.57e-05	0.000277	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—thyroid cancer	1.57e-05	0.000277	CcSEcCtD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—thyroid cancer	1.57e-05	0.000853	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—KRAS—thyroid cancer	1.57e-05	0.000853	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—KRAS—thyroid cancer	1.57e-05	0.000853	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TPR—thyroid cancer	1.57e-05	0.000852	CbGpPWpGaD
Temsirolimus—Headache—Doxorubicin—thyroid cancer	1.56e-05	0.000275	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—KRAS—thyroid cancer	1.56e-05	0.000845	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PRKAR1A—thyroid cancer	1.54e-05	0.000838	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—KRAS—thyroid cancer	1.54e-05	0.000838	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—KRAS—thyroid cancer	1.54e-05	0.000834	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—HRAS—thyroid cancer	1.53e-05	0.000832	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—MINPP1—thyroid cancer	1.53e-05	0.00083	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRG1—thyroid cancer	1.52e-05	0.000827	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SST—thyroid cancer	1.52e-05	0.000825	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRG1—thyroid cancer	1.52e-05	0.000824	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—HRAS—thyroid cancer	1.51e-05	0.000819	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TCF7L1—thyroid cancer	1.5e-05	0.000815	CbGpPWpGaD
Temsirolimus—Nausea—Doxorubicin—thyroid cancer	1.48e-05	0.000261	CcSEcCtD
Temsirolimus—MTOR—Disease—MEN1—thyroid cancer	1.48e-05	0.000801	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CALCA—thyroid cancer	1.46e-05	0.000794	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—KRAS—thyroid cancer	1.45e-05	0.000789	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—HRAS—thyroid cancer	1.45e-05	0.000786	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—HRAS—thyroid cancer	1.44e-05	0.000782	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—MINPP1—thyroid cancer	1.44e-05	0.000782	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	1.43e-05	0.000778	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—HRAS—thyroid cancer	1.43e-05	0.000778	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—thyroid cancer	1.43e-05	0.000774	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—HRAS—thyroid cancer	1.42e-05	0.00077	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—AKT1—thyroid cancer	1.41e-05	0.000768	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	1.4e-05	0.000759	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PTEN—thyroid cancer	1.39e-05	0.000756	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	1.39e-05	0.000755	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—AKT1—thyroid cancer	1.39e-05	0.000755	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TERT—thyroid cancer	1.36e-05	0.000739	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thyroid cancer	1.35e-05	0.000734	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	1.34e-05	0.000727	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—thyroid cancer	1.34e-05	0.000725	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	1.34e-05	0.000725	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—thyroid cancer	1.34e-05	0.000725	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—AKT1—thyroid cancer	1.33e-05	0.000723	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDK1—thyroid cancer	1.32e-05	0.000718	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—thyroid cancer	1.32e-05	0.000718	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—thyroid cancer	1.31e-05	0.000712	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—thyroid cancer	1.31e-05	0.000709	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HPGD—thyroid cancer	1.31e-05	0.000708	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HIF1A—thyroid cancer	1.3e-05	0.000707	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NDUFA13—thyroid cancer	1.3e-05	0.000705	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.28e-05	0.000696	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—AKT1—thyroid cancer	1.28e-05	0.000694	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—AKT1—thyroid cancer	1.27e-05	0.00069	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	1.27e-05	0.000687	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—AKT1—thyroid cancer	1.27e-05	0.000687	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—AKT1—thyroid cancer	1.26e-05	0.000684	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—AKT1—thyroid cancer	1.25e-05	0.00068	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NRAS—thyroid cancer	1.24e-05	0.000675	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—thyroid cancer	1.24e-05	0.000671	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	1.24e-05	0.00067	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NDUFA13—thyroid cancer	1.23e-05	0.000665	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CHST14—thyroid cancer	1.22e-05	0.000663	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	1.21e-05	0.000656	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	1.21e-05	0.000656	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.19e-05	0.000645	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	1.18e-05	0.000642	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	1.18e-05	0.00064	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—AKT1—thyroid cancer	1.18e-05	0.00064	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—AKT1—thyroid cancer	1.18e-05	0.00064	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CALCA—thyroid cancer	1.17e-05	0.000637	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—AKT1—thyroid cancer	1.17e-05	0.000634	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thyroid cancer	1.16e-05	0.000629	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—AKT1—thyroid cancer	1.15e-05	0.000626	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDK1—thyroid cancer	1.15e-05	0.000625	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CHST14—thyroid cancer	1.15e-05	0.000625	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.12e-05	0.000607	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IFNA2—thyroid cancer	1.11e-05	0.000601	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TSHR—thyroid cancer	1.1e-05	0.000596	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—AKT1—thyroid cancer	1.09e-05	0.000592	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PRKAR1A—thyroid cancer	1.08e-05	0.000587	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—BRAF—thyroid cancer	1.08e-05	0.000586	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KRAS—thyroid cancer	1.07e-05	0.000581	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDK1—thyroid cancer	1.06e-05	0.000577	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRG1—thyroid cancer	1.06e-05	0.000577	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	1.04e-05	0.000567	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—TPR—thyroid cancer	1.04e-05	0.000563	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MEN1—thyroid cancer	1.03e-05	0.000561	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	1.02e-05	0.000554	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—thyroid cancer	1.01e-05	0.00055	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HPGD—thyroid cancer	9.85e-06	0.000535	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TERT—thyroid cancer	9.54e-06	0.000518	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	9.51e-06	0.000516	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MINPP1—thyroid cancer	9.42e-06	0.000511	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTCH1—thyroid cancer	9.35e-06	0.000507	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HPGD—thyroid cancer	9.28e-06	0.000504	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRG1—thyroid cancer	9.25e-06	0.000502	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HIF1A—thyroid cancer	9.13e-06	0.000495	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—thyroid cancer	9.1e-06	0.000494	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.04e-06	0.000491	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—thyroid cancer	8.72e-06	0.000473	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	8.59e-06	0.000466	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SST—thyroid cancer	8.55e-06	0.000464	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRG1—thyroid cancer	8.54e-06	0.000463	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	8.29e-06	0.00045	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CALCA—thyroid cancer	8.23e-06	0.000446	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—AKT1—thyroid cancer	8.03e-06	0.000436	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NDUFA13—thyroid cancer	8.01e-06	0.000435	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PTEN—thyroid cancer	7.95e-06	0.000431	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—SLC5A5—thyroid cancer	7.77e-06	0.000421	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TERT—thyroid cancer	7.67e-06	0.000416	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PTEN—thyroid cancer	7.64e-06	0.000414	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTEN—thyroid cancer	7.6e-06	0.000413	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.6e-06	0.000412	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—BRAF—thyroid cancer	7.56e-06	0.00041	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CHST14—thyroid cancer	7.53e-06	0.000409	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TPR—thyroid cancer	7.5e-06	0.000407	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDK1—thyroid cancer	7.45e-06	0.000404	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	7.38e-06	0.0004	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HIF1A—thyroid cancer	7.33e-06	0.000398	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NRAS—thyroid cancer	7.09e-06	0.000385	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRAS—thyroid cancer	6.81e-06	0.00037	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRAS—thyroid cancer	6.78e-06	0.000368	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—RXRA—thyroid cancer	6.53e-06	0.000354	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.37e-06	0.000345	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—thyroid cancer	6.11e-06	0.000331	CbGpPWpGaD
Temsirolimus—MTOR—Disease—BRAF—thyroid cancer	6.07e-06	0.000329	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HPGD—thyroid cancer	6.07e-06	0.000329	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRG1—thyroid cancer	5.98e-06	0.000324	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—thyroid cancer	5.86e-06	0.000318	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—thyroid cancer	5.84e-06	0.000317	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TPR—thyroid cancer	5.66e-06	0.000307	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.66e-06	0.000307	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SLC5A5—thyroid cancer	5.61e-06	0.000305	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PRKAR1A—thyroid cancer	5.57e-06	0.000302	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—thyroid cancer	5.52e-06	0.000299	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TERT—thyroid cancer	5.37e-06	0.000291	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TPR—thyroid cancer	5.33e-06	0.000289	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—thyroid cancer	5.32e-06	0.000289	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	5.25e-06	0.000285	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—thyroid cancer	5.19e-06	0.000282	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HIF1A—thyroid cancer	5.13e-06	0.000279	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—thyroid cancer	4.98e-06	0.00027	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—thyroid cancer	4.96e-06	0.000269	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—thyroid cancer	4.9e-06	0.000266	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.78e-06	0.000259	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—thyroid cancer	4.75e-06	0.000258	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—RXRA—thyroid cancer	4.72e-06	0.000256	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—thyroid cancer	4.63e-06	0.000251	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—thyroid cancer	4.58e-06	0.000249	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—thyroid cancer	4.4e-06	0.000239	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—thyroid cancer	4.38e-06	0.000238	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—thyroid cancer	4.28e-06	0.000232	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—thyroid cancer	4.25e-06	0.000231	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC5A5—thyroid cancer	4.24e-06	0.00023	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—thyroid cancer	4.13e-06	0.000224	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PPARG—thyroid cancer	4.12e-06	0.000224	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—thyroid cancer	4.09e-06	0.000222	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC5A5—thyroid cancer	3.99e-06	0.000217	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—thyroid cancer	3.81e-06	0.000207	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—thyroid cancer	3.63e-06	0.000197	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—RXRA—thyroid cancer	3.56e-06	0.000193	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—thyroid cancer	3.56e-06	0.000193	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TPR—thyroid cancer	3.49e-06	0.000189	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—thyroid cancer	3.48e-06	0.000189	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.43e-06	0.000186	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—RXRA—thyroid cancer	3.35e-06	0.000182	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—thyroid cancer	3.28e-06	0.000178	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—thyroid cancer	3.24e-06	0.000176	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—thyroid cancer	3.1e-06	0.000168	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—thyroid cancer	3.07e-06	0.000166	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—thyroid cancer	3.02e-06	0.000164	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—thyroid cancer	2.99e-06	0.000162	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PPARG—thyroid cancer	2.98e-06	0.000162	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—thyroid cancer	2.83e-06	0.000153	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—thyroid cancer	2.79e-06	0.000151	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—thyroid cancer	2.67e-06	0.000145	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—thyroid cancer	2.67e-06	0.000145	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.61e-06	0.000142	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—thyroid cancer	2.46e-06	0.000134	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—thyroid cancer	2.34e-06	0.000127	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—thyroid cancer	2.3e-06	0.000125	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PPARG—thyroid cancer	2.25e-06	0.000122	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—RXRA—thyroid cancer	2.19e-06	0.000119	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPARG—thyroid cancer	2.12e-06	0.000115	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—thyroid cancer	2.04e-06	0.000111	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—thyroid cancer	2.04e-06	0.000111	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—thyroid cancer	1.95e-06	0.000106	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—thyroid cancer	1.77e-06	9.59e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—thyroid cancer	1.73e-06	9.36e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.67e-06	9.04e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—thyroid cancer	1.63e-06	8.84e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—thyroid cancer	1.54e-06	8.36e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—thyroid cancer	1.45e-06	7.88e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPARG—thyroid cancer	1.38e-06	7.51e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—thyroid cancer	1.18e-06	6.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.09e-06	5.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—thyroid cancer	9.5e-07	5.15e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—thyroid cancer	8.88e-07	4.82e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—thyroid cancer	8.37e-07	4.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—thyroid cancer	5.47e-07	2.97e-05	CbGpPWpGaD
